DailyStocks Stock Article Search

https://seekingalpha.com/news/4057313-teva-stock-raised-buy-jefferies?source=feed_tag_israel Jan 23, 2024 - Jefferies upgrades Teva Pharmaceutical (TEVA) to Buy from Hold ahead of the company's 2024 outlook citing multiple tailwinds to its business. Read more here. 0

https://www.zacks.com/stock/news/2216435/unveiling-teva-pharmaceutical-industries-ltd-teva-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2216435 Jan 26, 2024 - Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023. 0

https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html Jan 28, 2024 - Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years. 0

https://www.zacks.com/stock/news/2218858/teva-pharmaceutical-industries-ltd-teva-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2218858 Jan 31, 2024 - Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://seekingalpha.com/news/4065532-teva-stock-upgraded-piper-sandler-valuation?source=feed_tag_israel Feb 12, 2024 - Piper Sandler upgraded Teva Pharmaceutical (TEVA) to Overweight and raised its price target to $19 from $12 per share citing valuation. Read more here. 0

https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold. 0

https://seekingalpha.com/news/4071489-teva-and-jiangsu-announce-partnership-for-distribution-of-austedo-in-china?source=feed_tag_israel Feb 26, 2024 - Teva Pharmaceutical and Jiangsu Nhwa forge a strategic partnership to enhance patient access to AUSTEDO, a drug for neurodegenerative and movement... 0

https://seekingalpha.com/article/4680308-teva-pharmaceutical-industries-potential-outweighs-concerns?source=feed_tag_israel Mar 25, 2024 - Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations. The new CEO's turnaround plan looks promising. Find out why TEVA stock is a Buy. 0

https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567 Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition. 0

https://seekingalpha.com/news/4084589-teva-on-track-for-seventh-straight-day-of-gains?source=feed_tag_israel Mar 27, 2024 - Teva Pharmaceutical (TEVA) shares are on the rise, gaining for the 7th consecutive day. 0